Vivodyne
About Vivodyne
Vivodyne develops lifelike human organs for drug testing and research purposes. The company utilizes robotic systems and artificial intelligence to create realistic human tissues that simulate various organ functions. This innovative approach allows for efficient testing of pharmaceuticals, aiming to replace traditional animal testing methods. By producing over 100,000 human tissues in a short timeframe, Vivodyne enhances the predictive accuracy of drug responses in humans. The organization is committed to improving the preclinical drug testing process, providing valuable insights that can lead to more effective therapies. Through its advanced technology, Vivodyne contributes to the evolution of biomedical research and development.
Open positions (3)
Company details
Funding
Total raised
$78M
Last stage
Series A
Investors
Founders
Andrei Georgescu
PhD in bioengineering from the University of Pennsylvania (Dan Huh's lab). Co-founded Vivodyne in 2020. Expertise in human-tissue engineering, robotics, and machine learning.
LinkedInDan Huh
Professor of Bioengineering at the University of Pennsylvania. Internationally acclaimed pioneer of organ-on-a-chip technology, known for publishing the first 'lung-on-a-chip' model in Science while at Harvard.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.